001434703 000__ 05172cam\a2200661\i\4500
001434703 001__ 1434703
001434703 003__ OCoLC
001434703 005__ 20230309003814.0
001434703 006__ m\\\\\o\\d\\\\\\\\
001434703 007__ cr\un\nnnunnun
001434703 008__ 210216s2021\\\\sz\a\\\\ob\\\\001\0\eng\d
001434703 019__ $$a1237849666$$a1237870627
001434703 020__ $$a3030568245$$q(electronic book)
001434703 020__ $$a9783030568245$$q(electronic bk.)
001434703 020__ $$z3030568237
001434703 020__ $$z9783030568238
001434703 0247_ $$a10.1007/978-3-030-56824-5$$2doi
001434703 035__ $$aSP(OCoLC)1241066818
001434703 040__ $$aDKU$$beng$$erda$$epn$$cDKU$$dOCLCO$$dOCLCQ$$dYDXIT$$dEBLCP$$dGW5XE$$dYDX$$dOCLCO$$dOCLCF$$dUKAHL$$dOCL$$dOCLCQ$$dOCLCO$$dCOM$$dN$T$$dOCLCQ
001434703 049__ $$aISEA
001434703 050_4 $$aRC927$$b.R44 2021
001434703 08204 $$a616.723$$223
001434703 24500 $$aRheumatic diseases and syndromes induced by cancer immunotherapy :$$ba handbook for diagnosis and management /$$cMaria E. Suarez-Almazor, Leonard H. Calabrese, editors.
001434703 264_1 $$aCham, Switzerland :$$bSpringer,$$c[2021]
001434703 300__ $$a1 online resource (xiv, 363 pages) :$$billustrations (some color)
001434703 336__ $$atext$$btxt$$2rdacontent
001434703 337__ $$acomputer$$bc$$2rdamedia
001434703 338__ $$aonline resource$$bcr$$2rdacarrier
001434703 347__ $$atext file
001434703 347__ $$bPDF
001434703 504__ $$aIncludes bibliographical references and index.
001434703 5050_ $$aPart I. Introduction. Cancer Immunology and the evolution of immunotherapy ; Cancer immunotherapy: overview of immune checkpoint inhibitors ; Immunopathogenesis of immune-related adverse events from cancer immunotherapy -- Part II. Immune-related adverse events with immune-checkpoint inhibitors. Arthritis ; Polymyalgia rheumatica ; Myositis ; Sicca syndromes ; Sarcoidosis ; Miscellaneous rheumatic syndromes ; Non-rheumatic immune-related adverse events ; Immune-related adverse events with other cancer immunotherapies -- Part III. Cancer immunotherapy in patients with pre-existing rheumatic diseases. Inflammatory arthritis ; Other rheumatic autoimmune diseases -- Part IV. General principles of management. Management of rheumatic immune-related adverse events (irAEs): general principles ; Benefit-risk considerations ; Patient education and shared-decision making.
001434703 506__ $$aAccess limited to authorized users.
001434703 520__ $$aWith the increasing use of immune checkpoint inhibitors (ICI) across various cancers, the trends for indication at earlier stages, and the use of combination immunotherapy, the frequency of ICI-induced immune-related adverse events (irAE) is expected to grow substantially. Management of these irAE is challenging as it requires not only consideration of the toxicity but also risk-benefit ratios with respect to the primary cancer. Several rheumatic irAE have been reported with ICI therapy including arthritis, myositis, polymyalgia-like syndromes, sicca/Sjogren-like manifestations, and several other less common systemic autoimmune features commonly associated with connective tissue disease. This handbook provides clinicians with a comprehensive overview of the management of rheumatic irAE that develop from cancer immunotherapy. It focuses on the irAE seen with ICI, the most frequently used agents in treating cancer. It provides an overview of cancer immunology, immunotoxicity, and immunotherapies such as ICI, cytokine-based therapy, and CART. It examines the epidemiology, clinical manifestations, diagnosis, differential diagnosis, and treatment of a variety of rheumatic immune-related adverse events arising from these therapies. Chapters also cover cancer immunotherapy in patients with preexisting rheumatic diseases such as inflammatory arthritis and other connective tissue disorders. The book helps clinicians to distinguish the current types of cancer immunotherapy and general toxicity patterns, recognize and diagnose rheumatic clinical syndromes, understand the pathogenesis of irAE, and consider risk-benefit ratios when managing patients with rheumatic irAE. Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy is an essential resource for physicians and related professionals, residents, fellows, graduate students and nurses alike in rheumatology, clinical immunology, oncology, and internal medicine.
001434703 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed April 1, 2021).
001434703 650_0 $$aRheumatism.
001434703 650_0 $$aImmunologic diseases.
001434703 650_0 $$aCancer$$xImmunotherapy$$xComplications.
001434703 650_0 $$aRheumatology.
001434703 650_0 $$aOncology.
001434703 650_0 $$aImmunology.
001434703 650_6 $$aRhumatisme.
001434703 650_6 $$aMaladies immunologiques.
001434703 650_6 $$aCancer$$xImmunothérapie$$xComplications et séquelles.
001434703 650_6 $$aRhumatologie.
001434703 650_6 $$aCancérologie.
001434703 650_6 $$aImmunologie.
001434703 655_0 $$aElectronic books.
001434703 7001_ $$aSuarez-Almazor, Maria E.,$$eeditor.
001434703 7001_ $$aCalabrese, Leonard H.,$$eeditor.
001434703 77608 $$iPrint version:$$z9783030568238
001434703 77608 $$iPrint version:$$z9783030568252
001434703 852__ $$bebk
001434703 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-030-56824-5$$zOnline Access$$91397441.1
001434703 909CO $$ooai:library.usi.edu:1434703$$pGLOBAL_SET
001434703 980__ $$aBIB
001434703 980__ $$aEBOOK
001434703 982__ $$aEbook
001434703 983__ $$aOnline
001434703 994__ $$a92$$bISE